1 Cress WD,Seto E.Histone deacetylases,transcriptional control,and cancer[J].J Cell Physiol,2000;184:1-16 2 FronsdalK ,Saatcioglu F.Histone deacetylase inhibitors differen-tially mediate apoptosis in prostate cancercells[J].Prostate,2005;62:299-306 3 GrossmannME,Huang H,Tindall DJ.Androgen receptorsignal-ing in androgen-refractory prostate cancer[J].J Natl CancerInst,2001;93:1687-97 4 Koivisto P,Kononen J,Palmberg C,Tammela T,Hyytinen E,Iso-la J,et al.Androgen receptorgene amplification:a possible mo-lecularmechanism forandrogen deprivation therapy failure in prostate cancer[J].CancerRes,1997;57:314-9 5 PrinsGS,Sklarew RJ,Pertschuk LP.Image analysis of androgen receptorimmunostaining in prostate canceraccurately predicts response to hormonal therapy[J].J Urolo,1998;159:641-9 6 Tsurutani J,Soda H,OkaM ,SuenagaM ,Doi S,Nakamura Y,et al.Antiproliferative effects of the histone deacetylase inhibitorFR901228 on small-cell lung cancerlines and drug-resistant sublines[J].Int J Cancer,2003;104:238-42 7 Deroanne CF,Bonjean K,Servotte S,Devy L,Colige A,Clausse N,et al.Histone deacetylases inhibitors as anti-angiogenic agents altering vascularendothelial growth factorsignaling[J].Oncogene,2002;21:427-36 8 Liu LT,Chang HC,Chiang LC,Hung WC.Histone Deacetylase InhibitorUp-Regulates RECK to Inhibit MMP-2 Activation and CancerCell Invasion[J].CancerRes,2003;63:3069-72 9 Boyes J,ByfieldP,Nakatani Y,Ogryzko V.Regulation of activi-ty of the transcription factorGATA-1 by acetylation[J].Nature,1998;396:594-8 10 Yu X,Guo ZS,Marcu MG ,Neckers L,Nguyen DM ,Chen GA,et al.Modulation of p53,ErbB1,ErbB2,and Raf-1 expression in lung cancercells by depsipeptide FR901228[J].J Natl Can-cerInst,2002;94:504-13 |